1. Home
  2. Neutropenia
  Subject:

Neutropenia   New Search

View on DBpedia    View on Wikipedia
Top related subjects:
 Chemotherapy Progression-free survival Thrombocytopenia Diarrhea Anemia Leukopenia Enzyme inhibitor Paclitaxel Cisplatin Pharmacokinetics Neutropenia Radiation therapy Breast cancer Neoadjuvant therapy Metastasis Carcinoma Multivariate analysis Estrogen receptor Syndrome Fever Gene Constipation Hemoglobin Hemolysis Red blood cell Anorexia nervosa Protein Apoptosis Western blot Messenger RNA Carboplatin Blood plasma Bioavailability Biological half-life Pharmacodynamics
RELATED SUBJECTS:
The publications listed also have these subjects
Chemotherapy  18 times
Thrombocytopenia  13 times
Progression-free survival  13 times
Enzyme inhibitor  9 times
Diarrhea  8 times
Pharmacokinetics  7 times
Peripheral neuropathy  7 times
Leukopenia  7 times
Paclitaxel  6 times
Anemia  6 times
Carboplatin  5 times
Breast cancer  5 times
Syndrome  4 times
Neu!  4 times
Lymphoma  4 times
Fever  4 times
Confidence interval  4 times
Colorectal cancer  4 times
Cisplatin  4 times
Anorexia nervosa  4 times
Stomatitis  3 times
Protein  3 times
Neutrophil  3 times
Lymphocytopenia  3 times
Hematopoietic stem cell transplantation  3 times
Gemcitabine  3 times
Estrogen receptor  3 times
Dexamethasone  3 times
ClinicalTrials.gov  3 times
Clinical trial  3 times
China  3 times
Blood plasma  3 times
Bacteremia  3 times
Alanine transaminase  3 times
Trastuzumab  2 times
Single-nucleotide polymorphism  2 times
Rituximab  2 times
Polymerase  2 times
Placebo  2 times
Performance status  2 times
Ovarian cancer  2 times
Neoadjuvant therapy  2 times
Necrosis  2 times
Multivariate analysis  2 times
Monoclonal antibody  2 times
MEDLINE  2 times
Lymph node  2 times
Leukemia  2 times
Irinotecan  2 times
Hypertension  2 times
Hormone  2 times
Growth factor  2 times
Endocrine system  2 times
Embase  2 times
Doxorubicin  2 times
Cyclophosphamide  2 times
Cyclin-dependent kinase 4  2 times
Chain reaction  2 times
Capecitabine  2 times
CT scan  2 times
Bortezomib  2 times
Biomarker  2 times
Biliary tract  2 times
B-cell chronic lymphocytic leukemia  2 times
Apoptosis  2 times
Antibiotics  2 times
Albumin  2 times
Adjuvant  2 times
Acute lymphoblastic leukemia  2 times
Acinetobacter baumannii  2 times
Acid  2 times
Xenotransplantation  1 time
Viral hepatitis  1 time
Vincristine  1 time
Vasculitis  1 time
Urinary tract infection  1 time
Univariate  1 time
Tyrosine-kinase inhibitor  1 time
Tyrosine kinase  1 time
Triple-negative breast cancer  1 time
Transport Layer Security  1 time
Transaminase  1 time
Topoisomerase  1 time
TimesDaily  1 time
Thailand  1 time
Targeted therapy  1 time
TNBC  1 time
T cell  1 time
Sunitinib  1 time
Sulfamethoxazole  1 time
Sorafenib  1 time
Sodium  1 time
Socioeconomic status  1 time
Shortness of breath  1 time
Septic shock  1 time
Sepsis  1 time
Schutzstaffel  1 time
Sarcoma  1 time
Salvage therapy  1 time
SPSS  1 time
Rotavirus  1 time
Root of the lung  1 time
Ribavirin  1 time
Retinopathy  1 time
Radiation therapy  1 time
Race and ethnicity in the United States Census  1 time
Purpura  1 time
Pseudomonas aeruginosa  1 time
Proteinuria  1 time
Pneumothorax  1 time
Pneumonia  1 time
Pleural effusion  1 time
Pharmacovigilance  1 time
Pharmacology  1 time
Parasitism  1 time
Pancreatic cancer  1 time
P-glycoprotein  1 time
Oxaliplatin  1 time
Ovid Technologies  1 time
Odds ratio  1 time
Non-small-cell lung carcinoma  1 time
Neurological disorder  1 time
National Comprehensive Cancer Network  1 time
Mycobacterium tuberculosis  1 time
Munhwa Broadcasting Corporation  1 time
Multiple myeloma  1 time
Mitomycins  1 time
Milan  1 time
Methotrexate  1 time
Methicillin  1 time
Metabolism  1 time
Mediastinum  1 time
Malaria  1 time
Lumbar vertebrae  1 time
Los Angeles  1 time
Logistic regression  1 time
Lipase  1 time
Leukoencephalopathy  1 time
Kinase  1 time
Italy  1 time
Iran  1 time
Intraperitoneal injection  1 time
Interim analysis  1 time
Institutional review board  1 time
India  1 time
Incremental cost-effectiveness ratio  1 time
Imatinib  1 time
Hyperthermic intraperitoneal chemotherapy  1 time
Hyperphosphatemia  1 time
Hyperglycemia  1 time
Histone deacetylase inhibitor  1 time
Histone deacetylase  1 time
Hepatotoxicity  1 time
Hepatitis C virus  1 time
Hepatitis C  1 time
Hematology  1 time
Haematopoiesis  1 time
HIV  1 time
Granulocyte colony-stimulating factor  1 time
Gram-negative bacteria  1 time
Globulin  1 time
Giardia lamblia  1 time
Gel electrophoresis  1 time
France  1 time
Folinic acid  1 time
Fluorouracil  1 time
Fluorescence  1 time
Fibroblast  1 time
Extracorporeal membrane oxygenation  1 time
Ethylenediaminetetraacetic acid  1 time
Escherichia coli  1 time
Epidemiology  1 time
Endocarditis  1 time
Eastern Cooperative Oncology Group  1 time
ELISA  1 time
Disease  1 time
Dengue fever  1 time
Demyelinating disease  1 time
Dementia  1 time
Decision problem  1 time
Dasatinib  1 time
DNA  1 time
Cytotoxic T cell  1 time
Cytomegalovirus  1 time
Cytochrome P450  1 time
Cutaneous condition  1 time
Cryptosporidium  1 time
Crizotinib  1 time
Creatinine  1 time
Corticosteroid  1 time
Constipation  1 time
Cocaine  1 time
Cmax (pharmacology)  1 time
Classical mechanics  1 time
Ciprofloxacin  1 time
Chronic myelogenous leukemia  1 time
Cholangiocarcinoma  1 time
Cell cycle  1 time
Ceftazidime  1 time
Carbapenem  1 time
CYP3A4  1 time
CYP2D6  1 time
CD20  1 time
Bronchoalveolar lavage  1 time
Bootstrapping  1 time
Blood urea nitrogen  1 time
Bladder cancer  1 time
Biosimilar  1 time
Biology  1 time
Biological half-life  1 time
Biochemical cascade  1 time
Bioavailability  1 time
Bevacizumab  1 time
Beta-lactamase  1 time
Bcl-2  1 time
B-cell lymphoma  1 time
Axillary lymph nodes  1 time
Aureus  1 time
Aromatase inhibitor  1 time
Antiviral drug  1 time
Antimalarial medication  1 time
Antigen  1 time
Antiemetic  1 time
Anticoagulant  1 time
Antibody  1 time
Amylase  1 time
Amikacin  1 time
Alanine  1 time
Aircraft fabric covering  1 time
Agonist  1 time
Aflibercept  1 time
Adjuvant therapy  1 time
Adenocarcinoma  1 time
Acute myeloid leukemia  1 time
Acinetobacter  1 time
Acetylation  1 time

Publications tagged with this subject: 50

Note: Top 50 publications shown only. Open an item panel to view more info


1. Efficacy and safety of chemotherapy with or without targeted therapy in biliary tract cancer: A meta-analysis of 7 randomized controlled trials

2. Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study

3. Phase II study of induction gemcitabine and S-1 followed by chemoradiotherapy and systemic chemotherapy using S-1 for locally advanced pancreatic cancer

4. Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer

5. White Blood Cell Count of the scorpion fish Scorpaena porcus as a biomarker of anthropogenic pollution in the Black Sea coastal waters

6. Changes of haemogram and serum biochemistry in neonatal piglet diarrhoea associated with porcine rotavirus type A

7. Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study

8. The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic Leukemia

9. Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancers

10. The effectiveness and safety of same-day versus next-day administration of long-acting granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced neutropenia: a systematic review

11. Phase I dose escalation and pharmacokinetic study on the nanoparticle formulation of polymeric micellar paclitaxel for injection in patients with advanced solid malignancies

12. Neoadjuvant chemotherapy with trastuzumab, docetaxel, and carboplatin administered every 3 weeks for Japanese women with HER2-positive primary breast cancer: efficacy and safety

13. The time has come for new models in febrile neutropenia: a practical demonstration of the inadequacy of the MASCC score

14. Pulmonary toxicity after intraperitoneal mitomycin C: a case report of a rare complication of HIPEC

15. Performance and economic evaluation of the molecular detection of pathogens for patients with severe infections: the EVAMICA open-label, cluster-randomised, interventional crossover trial

16. How to Diagnose Early 5-Azacytidine-Induced Pneumonitis: A Case Report

17. The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer

18. Psoas muscle volume as a predictor of peripheral neurotoxicity induced by primary chemotherapy in ovarian cancers

19. Clinical Pharmacokinetics and Pharmacodynamics of Panobinostat

20. A Mechanism-Based PK/PD Model for Hematological Toxicities Induced by Antibody-Drug Conjugates

21. A prospective study of XELIRI plus bevacizumab as a first-line therapy in Japanese patients with unresectable or recurrent colorectal cancer (KSCC1101)

22. Co-administration of dexamethasone increases severity and accelerates onset day of neutropenia in bladder cancer patients on methotrexate, vinblastine, adriamycin and cisplatin chemotherapy: a retrospective cohort study

23. Phase IV Study of Sunitinib in Chinese Patients with Imatinib-Resistant or Imatinib-Intolerant Gastrointestinal Stromal Tumors

24. Interim analysis of a phase II trial evaluating the safety and efficacy of capecitabine plus oxaliplatin (XELOX) as adjuvant therapy in Japanese patients with operated stage III colon cancer

25. Antitumor activity and safety profile of weekly carboplatin plus paclitaxel in metastatic breast cancer: a ten-year, monocentric, retrospective study

26. Non-fermentative Gram-negative rods bacteremia in children with cancer: a 14-year single-center experience

27. TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies

28. A phase I and pharmacokinetic study of afilbercept with FOLFIRI: comparison of Chinese and Caucasian populations

29. Impact of recommended weight-based dosing of granulocyte-colony stimulating factors in acute leukemia and stem cell transplant patients

30. Association between dementia and reduced walking ability and 30-day mortality in patients with extended-spectrum beta-lactamase-producing Escherichia coli bacteremia

31. Successful rescue combination of extracorporeal membrane oxygenation, high-frequency oscillatory ventilation and prone positioning for the management of severe methicillin-resistant Staphylococcus aureus pneumonia complicated by pneumothorax: a case

32. A phase I study of cilengitide and paclitaxel in patients with advanced solid tumors

33. Carboplatin instead of cisplatin in combination with dexamethasone, high-dose cytarabine with or without rituximab (DHAC+/−R) is an effective treatment with low toxicity in Hodgkin’s and non-Hodgkin’s lymphomas

34. A multicenter, single-arm, Phase II clinical trial of bendamustine monotherapy in patients with chronic lymphocytic leukemia in Japan

35. Adverse effects of levamisole in cocaine users: a review and risk assessment

36. Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC

37. Short stature: an ordinary sign for an unordinary diagnosis

38. Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1/2 study

39. Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma

40. Cryptosporidium infection in children with cancer undergoing chemotherapy: how important is the prevention of opportunistic parasitic infections in patients with malignancies?

41. Bortezomib combined with standard induction chemotherapy in Japanese children with refractory acute lymphoblastic leukemia

42. Incidence and risk factors of febrile neutropenia in patients with non-Hodgkin B-cell lymphoma receiving R-CHOP in a single center in Japan

43. Obinutuzumab: A Review in Rituximab-Refractory or -Relapsed Follicular Lymphoma

44. A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO)

45. Over- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study

46. Severe neutropenia revealing a rare presentation of dengue fever: a case report

47. Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study

48. Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis

49. Acinetobacter baumannii bacteraemia in patients with haematological malignancy: a multicentre retrospective study from the Infection Working Party of Jiangsu Society of Hematology

50. Safety of a fixed-dose combination of artesunate and amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in real-life conditions of use in Côte d’Ivoire


Questions?

Drop us a message.